Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16804836 | 1.00 | CA1 (0.36) | CA1CA9GRM4CYP2D6HTT | |
| SCHEMBL12104209 | 0.89 | CA1 (0.43) | CA1CA9 | |
| SCHEMBL353004 | 0.89 | CA1 (0.43) | CA1CA9 | |
| SCHEMBL15334751 | 0.89 | CA1 (0.43) | CA1CA9 | |
| SCHEMBL12104249 | 0.81 | TSHR (0.42) | CA1CA9CYP2D6 | |
| SCHEMBL12108374 | 0.81 | CYP2C9 (0.42) | CA1CA9TDP1 | |
| SCHEMBL12104240 | 0.81 | TSHR (0.42) | CA1CA9CYP2D6 | |
| SCHEMBL16144167 | 0.81 | CYP2C9 (0.42) | CA1CA9TDP1 | |
| SCHEMBL3628734 | 0.79 | CA1 (0.40) | CA1CA9CYP2D6 | |
| SCHEMBL17323381 | 0.76 | CA1 (0.39) | CA1CA9HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-18 | — | — | US | disclosed |
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166532-A1 | HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES | RPL17, RPL26, RPL35 | CA1 2858/4885CA9 2822/4885GRM4 3091/4885 |
| US-20160046661-A1 | RAS INHIBITORS AND USES THEREOF | KRAS, NRAS, RASGRP1 | CA1 2892/4885CA9 419/4885GRM4 4769/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | CA1 2926/4885CA9 3154/4885GRM4 2375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.